Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced, effective January 19, 2026: (i), Paul Mann, the founder and Executive Chairman of ASP Isotopes Inc. (the "Company"), will resume his role as the Company's Chief Executive Officer and continue as Executive Chairman, and (ii) Robert Ainscow, who serves as Interim Chief Executive Officer during Mr. Mann's medical leave of absence, will continue in his position as Chief Operating Officer.

Biographical and other information for Paul Mann is set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 25, 2025 and is incorporated herein by reference. There is no arrangement or understanding between Mr. Mann and any other person, pursuant to which he was selected as an officer. The Company has not entered into, amended, or modified any plan, contract, arrangement, grant, or award in connection with Mr. Mann's re-appointment as Chief Executive Officer.